The Role of PGC-1α in Neurodegenerative Diseases: Molecular Mechanisms, Translational Challenges, and Therapeutic Potential.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and preclinical research without new human clinical data.
PubMed 42430091 · doi:10.1007/s12035-026-06029-x
What was done
This narrative review synthesized preclinical and mechanistic literature evaluating the role of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) across neurodegenerative diseases (including Alzheimer's, Parkinson's, Huntington's, polyglutamine disorders, and ALS), examining therapeutic strategies and translational hurdles.
What was found
No quantitative findings or numerical data are reported in the abstract. PGC-1α functions as a context-dependent regulator of mitochondrial biogenesis, oxidative phosphorylation, antioxidant defenses, and proteostasis. Preclinical restoration of PGC-1α signaling improved mitochondrial metrics and reduced neuronal injury, whereas broad or sustained activation caused limited benefit or maladaptive outcomes.
Why it matters
The paper frames PGC-1α as a tunable rheostat rather than a simple on/off neuroprotective switch, outlining why precision targeting of specific cell types, isoforms, and disease stages is necessary for clinical translation.
Limits
The paper is a narrative review containing no original human clinical data. Therapeutic strategies remain largely preclinical and face unresolved challenges in CNS delivery, pathway selectivity, validated target-engagement biomarkers, and potential off-target or overdose toxicity.
Cited by
- supports PGC-1alpha promotes mitochondrial biogenesis and enhances cellular energy metabolism across the body, including in microglial cells.